Browse ST14

Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type II membrane protein
Domain PF00431 CUB domain
PF00057 Low-density lipoprotein receptor domain class A
PF01390 SEA domain
PF00089 Trypsin
Function

Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001763 morphogenesis of a branching structure
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0002064 epithelial cell development
GO:0003382 epithelial cell morphogenesis
GO:0008544 epidermis development
GO:0009913 epidermal cell differentiation
GO:0014020 primary neural tube formation
GO:0016331 morphogenesis of embryonic epithelium
GO:0021915 neural tube development
GO:0030216 keratinocyte differentiation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0043588 skin development
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060669 embryonic placenta morphogenesis
GO:0060670 branching involved in labyrinthine layer morphogenesis
GO:0060671 epithelial cell differentiation involved in embryonic placenta development
GO:0060672 epithelial cell morphogenesis involved in placental branching
GO:0060706 cell differentiation involved in embryonic placenta development
GO:0060711 labyrinthine layer development
GO:0060713 labyrinthine layer morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061458 reproductive system development
GO:0072175 epithelial tube formation
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0016323 basolateral plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-6809371: Formation of the cornified envelope
R-HSA-6805567: Keratinization
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ST14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ST14 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22139080Colon AdenocarcinomaPromote immunitySuppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Here, we show that intestinal epithelial-specific ablation of St14 in mice causes formation of colon adenocarcinoma with very early onset and high penetrance.
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ST14 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ST14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2050.715
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2730.858
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5680.576
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5860.295
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9290.724
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1440.963
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3670.515
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5680.618
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0440.974
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1060.413
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5750.78
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0450.701
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ST14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST14.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ST14 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ST14 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolST14
Namesuppression of tumorigenicity 14 (colon carcinoma)
Aliases SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location11q24-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ST14 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ST14.
ID Name Drug Type Targets #Targets
DB00013UrokinaseBiotechLRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......10
DB03127BenzamidineSmall MoleculeATOX1, CSNK2A1, ECI1, KLK1, KLK6, PLAU, PRSS1, PRSS2, PRSS3, ST1410